Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.86 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15545108 | 0.92 | CNR2 (1.00) | CNR2HSD11B1MEN1MAPTKMT2A | |
| SCHEMBL16661713 | 0.86 | CNR2 (0.88) | CNR2HSD11B1L3MBTL1MEN1MAPT | |
| SCHEMBL15545013 | 0.79 | CNR2 (1.00) | CNR2HSD11B1POLB | |
| SCHEMBL10914380 | 0.78 | L3MBTL1 (0.57) | CNR2L3MBTL1MEN1MAPTKMT2A | |
| SCHEMBL28598365 | 0.77 | L3MBTL1 (0.59) | CNR2L3MBTL1MEN1MAPTKMT2A | |
| SCHEMBL14591324 | 0.77 | NOTUM (0.59) | CNR2L3MBTL1MEN1MAPTKMT2A | |
| SCHEMBL15546000 | 0.77 | CNR2 (0.72) | CNR2HSD11B1MEN1KMT2AALDH1A1 | |
| SCHEMBL15587303 | 0.76 | CNR2 (0.52) | CNR2HSD11B1L3MBTL1MEN1MAPT | |
| SCHEMBL15545590 | 0.74 | CNR2 (1.00) | CNR2HSD11B1MEN1MAPTKMT2A | |
| SCHEMBL23716019 | 0.73 | L3MBTL1 (0.58) | CNR2L3MBTL1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2870139-B1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-06-15 | — | — | EP | claimed |
| US-9090615-B2 | Adamantyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | claimed |
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-04-23 | — | — | US | claimed |
| EP-2870139-B1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-06-15 | — | — | EP | disclosed |
| US-9090615-B2 | Adamantyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090615-B2 | Adamantyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090615-B2 | Adamantyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2870139-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-05-13 | — | — | EP | disclosed |
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2014005968-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | CNR1, CNR2, GPR18 | CNR2 2/4885HSD11B1 1447/4885L3MBTL1 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.